Phaseline

Companies › NewAmsterdam Pharma

NewAmsterdam Pharma: clinical trials, targets and expected readouts

3 active drug programs in 26 registered trials: 12 Phase 4, 7 Phase 3, 7 Phase 2; Neurology, Cardiovascular, Metabolic and endocrine, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
obicetrapib
Cholesteryl ester transfer protein inhibitor
CETPPhase 3Atherosclerotic Cardiovascular Disease; Lipidemia; Dyslipidemias; Antioxidant Absorption …Nov 2026
ezetimibe
Niemann-Pick C1-like protein 1 inhibitor
NPC1L1Phase 3Lipidemia; Atherosclerotic Cardiovascular Disease With Dyslipidemia; Atherosclerotic Cardiovascular Disease (ASCVD); Type 1 Diabetes …Nov 2027
evolocumab
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 2Dyslipidemias; Type 1 Diabetes; Stroke, Ischemic; STEMI - ST Elevation Myocardial Infarction …Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05537948evolocumabPhase 4DyslipidemiasMetabolic and endocrineJan 2024
NCT06784557ezetimibePhase 4Atherosclerotic Cardiovascular Disease With DyslipidemiaCardiovascularJul 2025
NCT06081803evolocumabPhase 3ST Elevation Myocardial InfarctionCardiovascularDec 2025
NCT05202509obicetrapibPhase 3Atherosclerotic Cardiovascular DiseaseCardiovascularNov 2026
NCT06496243obicetrapibPhase 2DyslipidemiasCardiovascularNov 2026
NCT06496243evolocumabPhase 2DyslipidemiasCardiovascularNov 2026
NCT06982508obicetrapibPhase 2Antioxidant AbsorptionOtherDec 2026
NCT07839741ezetimibePhase 4Atherosclerotic Cardiovascular Disease (ASCVD)CardiovascularJan 2027
NCT05641753ezetimibePhase 4Type 1 DiabetesMetabolic and endocrineJul 2027
NCT05641753evolocumabPhase 4Type 1 DiabetesMetabolic and endocrineJul 2027
NCT04499859ezetimibePhase 4Myocardial InfarctionCardiovascularAug 2027
NCT06305559obicetrapibPhase 3LipidemiaCardiovascularNov 2027
NCT06305559ezetimibePhase 3LipidemiaCardiovascularNov 2027
NCT03753555evolocumabPhase 4Stroke, IschemicNeurologyNov 2027
NCT04968509evolocumabPhase 3Aortic StenosisCardiovascularDec 2027
NCT06437574ezetimibePhase 2Prostate CancerOncologyFeb 2028
NCT07219602obicetrapibPhase 3LipidemiaMetabolic and endocrineMar 2028
NCT07219602obicetrapibPhase 3LipidemiaMetabolic and endocrineMar 2028
NCT04951856evolocumabPhase 4STEMI - ST Elevation Myocardial InfarctionCardiovascularMay 2028
NCT07794670obicetrapibPhase 2Preclinical Alzheimer's DiseaseNeurologySep 2028
NCT06284564evolocumabPhase 2Metastatic Renal Cell CarcinomaOncologyOct 2028
NCT07612774evolocumabPhase 4CoronaryCardiovascularOct 2028
NCT06186037ezetimibePhase 4Coronary Artery DiseaseCardiovascularFeb 2029
NCT07307989ezetimibePhase 2Ischemic StrokeNeurologyJul 2029
NCT06767774ezetimibePhase 4ASCVDMetabolic and endocrineAug 2029
NCT07611747ezetimibePhase 4Rheumatoid Arthritis (RA)ImmunologyApr 2031

From the company's SEC filings

Cash and short-term investments of $628m on 2026-09-30; operating cash outflow about $147m a year; runway about 51 months at that burn, to Jan 2031; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CETP (1) NPC1L1 (1) PCSK9 (1)

Companies with the same targets

DalCor Pharmaceuticals Novartis AstraZeneca Verve Therapeutics Amgen Merck & Co. (MSD) Innovent Biologics (Suzhou) Hasten Biopharmaceutical Regeneron Pharmaceuticals

Companies built like this

Lexicon Pharmaceuticals Eidos Therapeutics, a BridgeBio company Amylyx Pharmaceuticals Brainfarma Industria Química e Farmacêutica S/A THPharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.